The global genomics market, valued at USD 21.78 billion in 2025, is projected to reach approximately USD 116.92 billion by 2035, growing at a robust CAGR of 18.30%. This growth reflects increasing advancements in genomic research, diagnostics, and personalized medicine.

Genomics Market Statical Scope

Genomics is a commendable study of the organism's whole spectrum of DNA that learns the cell growth, structure, functions, and interactions. Genomics provides great coverage and exposure of all genes, and complex DNA brings more value to treatments and diagnostics. The use of genomics in the popular agriculture sector promotes enhancement in crop yields. The capacity of the market is visible in various medical spaces supporting pathogen tracking, precision medicine and diagnostics.

Consumer genomics is planting more growth seeds in the market, as per the business perspective. The high volume production of these genomics is driven by the trend and trust in precision medicine. The consumables and oncology segments are the main business sources for the market to earn fine revenue.

Genomics Market Share, By Region, 2025 (%)

• North America – The North America regional segment dominated the market by 43% of share due to the focus on personalized medicine as the cases of rare diseases and cancer are at a peak. The private and public funding are contributing largely to the regional genomics project.
• Europe – Europe covers 25% of the share with the perk of national genomics projects like Germany's GenomDE, Genomics England and Plan France Medicine Genomique 2025. This sub-regional effort promotes unity and the efforts of the regional market.
• Asia-Pacific – Asia Pacific covers 18% of the share due to popular integration of genomic profiling mainly for cancer research/treatment. The government is the backbone of the region due to the active participation and interest of the regional market leaders.
• LAMEA – The LAMEA held 14% of the share due to the rising cancer and genetic disorders. The famous AI technology is a commendable contributor to the regional market, as it handles massive data. This helps the genomic projects to take a lead in the healthcare space.

Genomics Market Share, By Application, 2025 (%)

• Functional Genomics – The functional genomics segment dominated the market by 33% of share due to the rise in drug discovery. The data unification and tech boon to the gene functions as it mimics the wide range of data files from metabolomics, proteomics and transcriptomics for further gene functions prediction.
• Biomarker Discovery – The segment leads by 25% with the genomics integration with the proteomics and transcriptomics, which gives clarity to the conditions. While liquid biopsies remain the popular growth factor in the segmental market.
• Epigenomics – The segment held 22% of the share as NGS has motivated researchers to apply base-pair solution navigation of the epigenome. The 3D structure and mapping chromatin availability promote 3D genome engineering. Single-cell epigenomics is a pillar of segmental growth.
• Pathway Analysis – The segment acquires 20% of profit due to the extended footprint of multi-omics unification. Following this, the advanced pathways analysis acknowledges various data types to get a great clarity of biological systems. The segment has evolved into effective engagements.

Genomics Market Share, By Deliverables, 2025 (%)

• Products – The products segment dominated the market by 70% of share due to the dominant production of systems and instruments. The software, featuring cloud-related data storage and AI-fuelled analysis, is introducing responsible segmental market growth.
• Services – The segment covers 30% of the share due to the massive popularity of outsourcing sequencing. The requirement for the data analysis is to bring tech precision to the knowledge of the market. Precision medicine is paving the way for the segmental market to practice precision.

Genomics Market Share, By End-Use, 2025 (%)

• Pharmaceutical and Biotechnology Companies – The pharmaceutical and biotechnology companies segment dominated the market by 55% due to the low cost of sequencing, encouraging advancements to fuel healthcare via the segment's contribution strength.
• Hospitals and Clinics – The segment leads by 15% of share, with the growing activities in the clinical settings due to the massive number of oncology testing and diagnostics. These lines of need for genomics profiles are popularly accelerating pharmacogenomics.
• Clinical Research – The segment held 12% of profit due to regional and national initiatives popularizing the importance of the market. The genomic profiles play a smart role in identifying the mutations, helping targeted therapies succeed in the clinical setting.
• Academic and Government Institutes – The segment held 10% of the share, with the awareness dive in the market confirming the excellence of precision medicine. The valuable investment in national biobanks is accelerating the segmental market growth.

Top Companies in the Genomics Market

• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies
• BGI Genomics
• QIAGEN N.V.
• Oxford Nanopore Technologies
• PacBio.
• Bio-Rad Laboratories, Inc.

Segments Covered in the Report

By Application

• Functional Genomics
• Epigenomics
• Pathway Analysis
• Biomarker Discovery

By Deliverables

• Products
• Services

By End Use

• Pharmaceutical and Biotechnology Companies
• Hospitals and Clinics
• Academic and Government Institutes
• Clinical Research

By Region

• North America
• Europe
• Asia-Pacific
• LAMEA